US DoD picks Evotec for rapid antibody development plan

5 July 2023

German multi-modal biotech Evotec (EVT: Xetra) has agreed terms for a $74 million project, building on work it has been undertaking on behalf of the US Department of Defense (DOD).

The money has been awarded to Evotec’s Seattle, USA-based subsidiary, Just-Evotec Biologics, and will be used to facilitate the rapid development of antibody candidates targeting orthopoxviruses.

A first contract under the Accelerated Antibodies program, for the development of biologic treatments for plague, was agreed in September 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK